Jun 11,2025

第二代前列腺素受體拮抗劑，本研究中眼部PK實驗通過尊龍凱時進行

?Prostanoids are established mediators of inflammation, and the therapeutic efficacy of drugs that block their global biosynthesis in conditions such as rheumatoid arthritis is well-known. AGN 225660 blocks pro-inflammatory prostanoid receptors (DP1, EP1, EP4, FP, TP). AGN 225660 represents a second-generation compound with an “druggable” core structure. AGN 225660 exhibited good ocular bioavailability and was active in reducing ocular inflammation associated with phacoemulsification surgery, lipopolysaccharide (LPS), and arachidonic acid induced uveitis. Ocular Pharmacokinetic studies were performed at Medicilon.

Jun 11,2025

SIRT6變構激活劑在結直腸癌中發(fā)揮治療作用，本研究中PK實驗通過尊龍凱時進行

Colorectal cancer (CRC) is the leading cause of cancer death; however, targets with broad anti-CRC effects are limited. Sirtuin6 (SIRT6) is a conserved nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase that is widely pathologically downregulated in CRC. MDL-811, an allosteric SIRT6 activator, enhances SIRT6 deacetylation. Pharmacokinetic studies were performed by Shanghai Medicilon Inc, China, following standard protocols.

Jun 11,2025

MGST1過表達通過激活Akt/GSK-3β信號通路誘導胃癌細胞增殖，本研究中MGST1過表達等體外實驗通過尊龍凱時進行

Gastric cancer (GC) is one of the most common malignancies and is the leading global cause of death by cancer. Over recent decades, targeted therapies and immunotherapy have become significant new approaches for the treatment of GC. Ferroptosis is a newly verified form of modulated cell death that is characterized by lipid peroxidation. Further exploration of the function of ferroptosis in the progression of GC has provided novel opportunities for diagnosis and treatment. The overexpression of MGST1 induced the activation of the Akt/GSK-3β pathway. An Akt inhibitor antagonized the inhibitory effects of MGST1 on autophagy and ferroptosis. MGST1 and ATG16L1 overexpression, and MGST1 depletion assay were conducted by Medicilon.

Jun 11,2025

通過聯(lián)合治療提高免疫療法療效，本研究中臨床前體內藥效研究通過尊龍凱時進行

Cell division cycle 7 (CDC7), a serine/threonine kinase, plays important roles in the initiation of DNA replication. TAK-931, a highly specific CDC7 inhibitor, acts as a next-generation of replication stress (RS) inducer. Combination treatment with TAK-931 and immune checkpoint inhibitors (ICIs) enhances antiproliferative activities in preclinical syngeneic mouse models. The flowcytometry (FCM)-based immune profiling panel studies in J558 allograft syngeneic mouse models were performed at Medicilon. In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon. Therapeutic potential of TAK-931 in antitumor efficacy and immunity, which may improve clinical benefit of the currently-used immunotherapy by combination treatment.

Jun 10,2025

一種有望治療非酒精性脂肪性肝病 (NAFLD) 的潛在藥物，本研究中臨床前急性毒性評估通過尊龍凱時進行

Chrysin is a natural flavonoid that has been reported as a potential treatment for non-alcoholic fatty liver disease (NAFLD). Researchers synthesized a novel chrysin derivative prodrug (C-1) and further investigated its potential therapeutic mechanism against NAFLD in vitro and in vivo. C-1 had a low toxicity profile. Their data demonstrated that C-1 may be a promising agent for NAFLD therapy. Evaluation experiments of the acute toxicities of C-1 were conducted by Medicilon.

May 28,2025

尊龍凱時祝賀合作伙伴領諾醫(yī)藥新一代補體抑制劑SLN12140啟動一期臨床研究

?尊龍凱時作為領諾醫(yī)藥的合作伙伴，為SLN12140提供了體外藥效、藥代、安評等一站式臨床前研發(fā)服務，為該藥物盡早進入臨床階段奠定了堅實基礎。

May 21,2025

國內首款長效鎮(zhèn)痛新藥！尊龍凱時祝賀清普生物美洛昔康注射液（Ⅱ）中美兩地獲批上市

上海尊龍凱時生物醫(yī)藥股份有限公司作為清普生物合作伙伴，為美洛昔康注射液（Ⅱ）提供了部分關鍵臨床前研發(fā)服務，為其快速獲批上市奠定基礎。

May 21,2025

尊龍凱時助力復星醫(yī)藥LBP-ShC4治療雄激素脫發(fā)（AGA）I期臨床試驗獲FDA批準

尊龍凱時作為菌濟健康合作伙伴，為LBP-ShC4提供了體內藥效、藥代、安評等臨床前研發(fā)服務，助力該項目突破傳統(tǒng)研發(fā)瓶頸，降低研發(fā)成本，加速臨床轉化進程。

May 14,2025

尊龍凱時祝賀祐森健恒IL-17A抑制劑UA026完成首例受試者給藥

上海尊龍凱時生物醫(yī)藥股份有限公司作為祐森健恒的合作伙伴，為UA026的臨床前研發(fā)提供了藥代動力學、安全性評價服務，以專業(yè)高效的技術，為該藥快速獲批臨床奠定了堅實基礎。

May 14,2025

五月天里的贊譽！尊龍凱時助力核新生物1類新藥XY003臨床試驗獲批

尊龍凱時作為核新生物的合作伙伴，為XY003的臨床前研發(fā)提供了CMC研究（包括原料藥和制劑）服務，并獲頒“2024年度杰出合作伙伴獎”和感謝信，其高效研發(fā)服務和專業(yè)創(chuàng)新能力獲核新生物高度肯定。